SPT-3001

SPT-3001 is an oral prodrug of allopregnanolone, an endogenous neurosteroid. It is being developed by Seaport Therapeutics for the treatment of anxious depression and other mood and anxiety disorders. Allopregnanolone has demonstrated therapeutic benefit in a range of neuropsychiatric conditions but is currently only approved as an intravenous infusion, limiting its clinical use. SPT-3001 leverages the Glyph platform to enhance oral bioavailability, avoid first-pass metabolism, and reduce hepatotoxicity and other side effects that have limited previous attempts at oral delivery of allopregnanolone. The drug aims to retain the activity and potency of endogenous allopregnanolone in an oral form, potentially enabling once-daily chronic dosing for patients with mood disorders[2][4].